Adaptimmune is a biotechnology company located in Philadelphia, Pennsylvania, specializing in innovative cellular therapies. Situated at 351 Rouse Blvd, the company focuses on advancing treatments that harness the power of the immune system to target diseases, primarily in the field of oncology. Adaptimmune’s approach involves developing engineered T-cell therapies designed to recognize and combat cancer cells more effectively, contributing to the growing landscape of personalized medicine.
Operating within the dynamic biotechnology sector of Philadelphia, Adaptimmune collaborates with scientific and medical communities to translate cutting-edge research into clinical applications. The company’s work is supported by extensive laboratory research, clinical trials, and partnerships that emphasize the potential of T-cell receptor (TCR) technology. This technology is central to Adaptimmune’s efforts to create targeted treatments that aim to improve patient outcomes through precise immune system engagement.
Adaptimmune’s presence in Philadelphia supports the city’s reputation as a hub for biomedical innovation and research. The company’s operations include research and development, manufacturing, and clinical trial management, all aimed at delivering novel therapeutic options. By focusing on cellular immunotherapy, Adaptimmune contributes to the advancement of biotechnology solutions that address complex medical challenges with an emphasis on safety and efficacy.
As part of the broader biotechnology industry in Pennsylvania, Adaptimmune plays a role in fostering growth and innovation in healthcare. Its ongoing research and development activities are critical to expanding the understanding of immune-based therapies. Through its scientific endeavors, Adaptimmune remains committed to exploring new frontiers in biotechnology to address unmet medical needs within the local and global healthcare communities.


































